Eurofins Scientific SE (ERFSF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ERFSF, $ (piyasa değeri 0) fiyatla Healthcare işi olan Eurofins Scientific SE'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 43/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 18 Mar 2026Eurofins Scientific SE (ERFSF) Sağlık ve Boru Hattı Genel Bakışı
Eurofins Scientific SE is a global leader in analytical testing and laboratory services, providing a comprehensive suite of solutions across diverse sectors, including food, environment, pharmaceuticals, and consumer products. The company's extensive network and scientific expertise position it as a key player in ensuring safety and quality standards worldwide.
Yatırım Tezi
Eurofins Scientific SE presents a compelling investment case due to its diversified service offerings and global presence in the analytical testing market. With a market capitalization of $12.91 billion, the company benefits from a stable revenue stream driven by regulatory requirements and increasing consumer demand for safety and quality. A gross margin of 22.5% and an ROE of 9.5% indicate solid profitability. Ongoing: The company's strategic acquisitions and expansion into high-growth areas such as biopharma and environmental testing are expected to drive future revenue growth. However, a debt-to-equity ratio of 96.84 and a beta of 0.94 suggest moderate financial risk and market sensitivity.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $12.91 billion reflects its significant presence in the analytical testing market.
- Profit margin of 6.5% indicates moderate profitability within the competitive diagnostics and research sector.
- Gross margin of 22.5% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Return on Equity (ROE) of 9.5% suggests efficient utilization of shareholder equity to generate profits.
- Debt-to-Equity ratio of 96.84 indicates a relatively high level of financial leverage.
Rakipler & Benzerleri
Güçlü Yönler
- Global presence with an extensive network of laboratories.
- Diversified service offerings across multiple industries.
- Strong reputation for scientific expertise and quality.
- Proven track record of strategic acquisitions and growth.
Zayıflıklar
- High debt-to-equity ratio.
- Exposure to regulatory changes and compliance risks.
- Dependence on acquisitions for growth.
- Potential for price competition in certain markets.
Katalizörler
- Upcoming: Expansion of biopharma testing services to capitalize on the growing biopharmaceutical industry.
- Ongoing: Strategic acquisitions to expand service offerings and geographic reach.
- Ongoing: Increasing focus on environmental testing to meet growing demand for environmental monitoring.
- Ongoing: Leveraging technological advancements to improve efficiency and accuracy of testing processes.
Riskler
- Potential: High debt-to-equity ratio could limit financial flexibility.
- Potential: Changes in regulatory requirements and compliance standards could increase costs.
- Potential: Economic downturns could reduce spending on testing services.
- Ongoing: Intense competition from other testing laboratories could put pressure on pricing.
- Potential: Product liability claims and recalls could damage reputation and financial performance.
Büyüme Fırsatları
- Expansion in Biopharma Testing: The biopharmaceutical industry is experiencing rapid growth, driven by the development of novel therapies and increasing regulatory scrutiny. Eurofins can capitalize on this trend by expanding its biopharma testing services, including drug discovery, clinical trials, and quality control. The global biopharmaceutical testing market is projected to reach $120 billion by 2027, offering significant growth potential for Eurofins. Timeline: Ongoing.
- Increasing Focus on Environmental Testing: Growing concerns about environmental pollution and climate change are driving demand for environmental testing services. Eurofins can leverage its expertise in water, air, and soil testing to capture a larger share of this market. The global environmental testing market is expected to reach $35 billion by 2026, presenting a substantial opportunity for Eurofins. Timeline: Ongoing.
- Growth in Food Safety Testing: With increasing consumer awareness of food safety and stricter regulations, the demand for food testing services is growing. Eurofins can expand its food testing capabilities, including allergen testing, GMO testing, and pesticide residue testing, to meet this demand. The global food safety testing market is projected to reach $22 billion by 2025, providing a significant growth avenue for Eurofins. Timeline: Ongoing.
- Penetration of Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid economic growth and increasing demand for testing and analytical services. Eurofins can expand its presence in these markets through strategic acquisitions and partnerships. The growth in these regions offers substantial opportunities for Eurofins to increase its global market share. Timeline: Ongoing.
- Strategic Acquisitions: Eurofins has a history of growth through strategic acquisitions. By acquiring smaller testing laboratories and specialized service providers, Eurofins can expand its service offerings, geographic reach, and customer base. This strategy allows Eurofins to quickly enter new markets and gain access to specialized expertise. Timeline: Ongoing.
Fırsatlar
- Expansion in high-growth areas such as biopharma and environmental testing.
- Penetration of emerging markets with increasing demand for testing services.
- Leveraging technological advancements to improve efficiency and accuracy.
- Increasing outsourcing of testing services by large corporations.
Tehditler
- Economic downturns and reduced spending on testing services.
- Increased competition from other testing laboratories.
- Changes in regulatory requirements and compliance standards.
- Potential for product liability claims and recalls.
Rekabet Avantajları
- Extensive network of laboratories across the globe.
- Wide range of testing services across various industries.
- Strong reputation for scientific excellence and customer service.
- Strategic acquisitions to expand service offerings and geographic reach.
ERFSF Hakkında
Founded in 1987 and headquartered in Luxembourg, Eurofins Scientific SE has grown from a small food testing laboratory to a global leader in analytical testing and laboratory services. The company's initial focus on food authenticity testing has expanded significantly to encompass a wide range of industries, including pharmaceuticals, environmental science, agriculture, and consumer products. Eurofins provides services such as agroscience, biopharma, clinical diagnostics, and consumer product testing. Its offerings include biological assessment, consumer and human safety testing, product chemistry, regulatory consultancy, and seed services. The company also provides assurance services, including sustainability audits, certification, quality inspection, and food and dietary supplement labeling. Eurofins operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste. It also offers specialized testing services such as forensic, genomic, maritime, materials and engineering, and sensory and consumer services. Eurofins' commitment to scientific excellence and customer service has driven its growth, making it a trusted partner for businesses seeking to ensure the safety, quality, and compliance of their products and processes.
Ne Yaparlar
- Provides analytical testing services for food, environment, pharmaceutical, and consumer products.
- Offers laboratory services, including water, air, and soil testing.
- Conducts biological assessments and product chemistry testing.
- Provides regulatory consultancy and seed services.
- Offers sustainability audits, certification, and quality inspection services.
- Provides clinical diagnostics and biopharma testing services.
- Offers forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services.
İş Modeli
- Generates revenue by providing analytical testing and laboratory services to various industries.
- Offers a wide range of testing services, including food, environment, pharmaceutical, and consumer products.
- Operates a network of laboratories across the globe, providing testing services for water, air, soil, building materials, and waste.
- Acquires smaller testing laboratories and specialized service providers to expand its service offerings and geographic reach.
Sektör Bağlamı
Eurofins Scientific SE operates in the diagnostics and research industry, which is characterized by increasing demand for testing and analytical services driven by stringent regulatory requirements and growing consumer awareness of safety and quality. The global market for testing, inspection, and certification is projected to reach $250 billion by 2028, growing at a CAGR of 4.5%. Eurofins competes with companies such as SGS SA, Intertek Group, and Bureau Veritas, offering a wide range of testing services across various sectors. The industry is also influenced by technological advancements, such as automation and data analytics, which are improving the efficiency and accuracy of testing processes.
Kilit Müşteriler
- Food manufacturers and processors
- Pharmaceutical companies
- Environmental agencies and organizations
- Consumer product manufacturers
- Government agencies
Finansallar
Grafik & Bilgi
Eurofins Scientific SE (ERFSF) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 Mar 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 Mar 2020
-
Stocks That Hit 52-Week Highs On Wednesday
· 4 Ara 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
ERFSF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
ERFSF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, ERFSF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
ERFSF OTC Piyasa Bilgileri
ERFSF, OTC Markets'in OTC Other piyasa katmanında işlem görmektedir.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
ERFSF Healthcare Hisse Senedi SSS
ERFSF için değerlendirilmesi gereken temel faktörler nelerdir?
Eurofins Scientific SE (ERFSF) şu anda yapay zeka skoru 43/100, düşük puanı gösteriyor. Temel güçlü yan: Global presence with an extensive network of laboratories.. İzlenmesi gereken birincil risk: Potential: High debt-to-equity ratio could limit financial flexibility.. Bu bir finansal tavsiye değildir.
ERFSF MoonshotScore'u nedir?
ERFSF şu anda MoonshotScore'da 43/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
ERFSF verileri ne sıklıkla güncellenir?
ERFSF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler ERFSF hakkında ne diyor?
ERFSF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
ERFSF'a yatırım yapmanın riskleri nelerdir?
ERFSF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: High debt-to-equity ratio could limit financial flexibility.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
ERFSF'ın P/E oranı nedir?
ERFSF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ERFSF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
ERFSF aşırı değerli mi, yoksa düşük değerli mi?
Eurofins Scientific SE (ERFSF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
ERFSF'ın temettü verimi nedir?
Eurofins Scientific SE (ERFSF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- The information provided in this dossier is based on available data and analysis as of March 18, 2026. Market conditions and company performance may change over time.
- AI analysis is pending and may provide further insights into the company's performance and prospects.